Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability
- 1 January 2007
- journal article
- review article
- Published by Informa UK Limited in Current Medical Research and Opinion
- Vol. 23 (12), 2985-2995
- https://doi.org/10.1185/030079907x242584
Abstract
Background: Non-steroidal, anti-inflammatory drugs (NSAIDs) are still the most widely used drugs worldwide. The introduction of selective cyclooxygenase (COX)‐2 inhibitors has led to compounds which appear less damaging to the gastrointestinal tract, but possibly more risky to the cardiovascular system than older drugs. None has as yet reached OTC-status. Objective: This situation necessitates an analysis of the characteristics of those older ones which – due to their relative safety – have achieved over-the-counter (OTC) status. Design: The pharmacodynamic and pharmacokinetic characteristics of non-selective COX inhibitors in OTC use were obtained from the literature by systematic search, examined and used to construct a coherent hypothesis why they achieved OTC status, i.e. effectiveness and relative safety at low doses. Results: Pharmacodynamic (COX‐2 preferential, but not selective inhibition) and, more importantly, pharmacokinetic characteristics of some of the older compounds may make them particularly safe drugs if used at low (OTC) doses with treatment limited to a few days of intake. The reason why some NSAIDs are particularly active while being relatively free from side-effects may be due to their specific biodistribution and metabolism, leading to drug accumulation and persistence in inflamed tissue (effect compartment) together with fast clearance from the central compartment, including blood, vascular wall, heart and kidney, i.e., possible side-effect compartments. Conclusion: This specific pharmacokinetic behavior of some non-selective COX inhibitors, such as diclofenac and ibuprofen, may explain why these widely used, non-steroidal, anti-inflammatory compounds are relatively well suited for OTC use and why some are more appropriate for the therapy of certain pain conditions than others.Keywords
This publication has 53 references indexed in Scilit:
- Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular MedicineCirculation, 2005
- STUDIES ON THE CHEMICAL REACTIVITY OF DICLOFENAC ACYL GLUCURONIDE WITH GLUTATHIONE: IDENTIFICATION OF DICLOFENAC-S-ACYL-GLUTATHIONE IN RAT BILEPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2003
- Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adultsPublished by Wiley ,2001
- Choosing the Right Nonsteroidal Anti-Inflammatory Drug for the Right PatientClinical Pharmacokinetics, 2000
- Cyclo‐oxygenase‐2: pharmacology, physiology, biochemistry and relevance to NSAID therapyBritish Journal of Pharmacology, 1999
- Pharmacokinetics of Nonsteroidal Anti-Inflammatory Drugs in Synovial FluidClinical Pharmacokinetics, 1999
- A comparison of synovial fluid concentrations of non-steroidal anti-inflammatory drugs with theirin vitro activityInflammation Research, 1991
- Effects of pirazolac on arachidonic acid metabolism in the human synovial systemCurrent Medical Research and Opinion, 1987
- Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritisEuropean Journal of Clinical Pharmacology, 1983
- Change of prostaglandin E level in joint fluids after treatment with flurbiprofen in patients with rheumatoid arthritis and osteoarthritis.Annals Of The Rheumatic Diseases, 1981